Paclitaxel

SKU: orb1310120

Description

Paclitaxel

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 33069-62-4
• MW: 853.91
• Purity: 99.72%
• Formula: C₄₇H₅₁NO₁₄
• SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
• Target: ADC Cytotoxin,Apoptosis,Microtubule Associated,Autophagy
• Solubility: DMSO:257.5 mg/mL (301.55 mM);Ethanol:21.4 mg/mL (25.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:8.54 mg/mL (10 mM)

Bioactivity

• Target IC50:
  1A9 cells:0.002 μM|1A9/ptx-22 cells:160.7 nM|HeLa cells:0.001 μM|CCRF-HSB-2 cells:0.25 µM|A431 cells:0.001 μM|B16 cells:0.04 μM|1A9/ptx-10 cells:157 nM|A375 cells:0.002 μM|4T1 cells:0.001 mM C6 cells:3.1 nM|Microtubule:4 nM|184B5 cells:2.32 μM|143B cells:5.56 μM|769-P cells:7.1 μM|A121 cells:6.1 nM
• In Vivo:
  METHODS: To investigat the effect of low-dose Paclitaxel on tumor invasion, Paclitaxel (2.6 mg/kg) was administered intraperitoneally to SCID mice bearing cholangiocarcinoma tumor EGI-1 once daily for two weeks. Results: Low-dose Paclitaxel treatment reduce the pulmonary spread of EGI-1 cells without significantly affecting their local tumor growth. METHODS: To develop a preclinical model of Paclitaxel alcohol-induced negative affective symptoms, Paclitaxel (2-8 mg/kg in 1 volume ethanol+1 volume Emulphor-620 +18 volumes distilled water) was injected intraperitoneally into C57BL/6J mice every four injections were given to C57BL/6J mice once every two days. Results: 8 mg/kg Paclitaxel treatment resulted in the development and maintenance of Mechanical and cold abnormalities of pain. Paclitaxel also induced anxiety-like and depressive-like behaviors. Paclitaxel produced behavioral Changes in the mouse affective state modeling assay, wherea the increase in injurious responses lasted longer.
• In Vitro:
  METHODS: Human T-cell lymphoblastic leukemia cells CCRF-HSB-2 were treated with Paclitaxel (0.01-1 µM) for 48 h. Cell growth Inhibition was detected by MTT. Results: Paclitaxel dose-dependently inhibite the growth of CCRF-HSB-2 cells with an IC50 of 0.25 µM METHODS: Human gastric cancer cells AGS were treated with Paclitaxel (10-160 nM) for 24-48 h the expression levels of target proteins were detected by Western Blot. Results: Paclitaxel induce the up-regulation o the expression of cleaved caspase-3 and cleaved PARP, which are apoptosis-related proteins. METHODS: Canine mammary tumor cells C mM were treated with Paclitaxel (0.01-1 μM) for 24 h. Apoptosis was detected using Flow Cytometry. Results: Paclitaxel dose-dependently induced apoptosis in C mM cells.
• Cell Research:
  × 0^4 cells are plated in 100 μL o the growth medium in the presence or absence of increasing concentration (0.1-1 μM) of taxol in 96-well plates and cultured at 37℃n 5% CO2 for 12-48 h the cells are then incubated with 25 μL of MTT (5 mg/mL) at 37℃or 4 h. After dissolvin the crystals with 0.04 N HCl in isopropanol the plates are read in a microplate reader at 570 nM.
• Animal Research:
  Adult (250-320 g) Male Sprague Dawley rats are used for All experiments. One week followin the DiI injection, rats are anesthetized with isofluorane and injected int the tail vein with 2 mg/kg paclitaxel or its Vehicle (1:1:23, cremophor EL:ethanol:0.9% saline) the tail vein injection is repeated three more times every Other day for a total of four injections .

Storage & Handling

• Storage: keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

MicrotubuleAssociated, Microtubule/Tubulin, Microtubule Associated, microtubule, inhibit, Paclitaxel, NSC125973, NSC-125973, NSC 125973, Inhibitor, ADC Payload, ADC Cytotoxin, ADCCytotoxin, Apoptosis, Autophagy, Taxol

Compound Identifiers

PubChem CID

36314